Literature DB >> 31075442

Grapefruit juice prolongs the QT interval of healthy volunteers and patients with long QT syndrome.

Ehud Chorin1, Aviram Hochstadt1, Yoav Granot1, Shafik Khoury1, Arie Lorin Schwartz1, Gilad Margolis1, Rami Barashi1, Dana Viskin1, Eihab Ghantous1, Michael Schnapper1, Tal Mekori1, Dana Fourey1, Milton Ernesto Guevara-Valdivia1, Manlio F Marquez1, David Zeltzer1, Raphael Rosso1, Sami Viskin2.   

Abstract

BACKGROUND: The list of medications linked to drug-induced long QT syndrome (LQTS) is diverse. It is possible that food products too have QT-prolonging potential.
OBJECTIVE: We tested the effects of grapefruit juice on the QT interval with the methodology used by the pharmaceutical industry to test new drugs.
METHODS: This was an open-label, randomized, crossover study with blinded outcome evaluation, a thorough QT study of grapefruit juice performed according to the Guidelines for the Clinical Evaluation of QT/QTc for Non-antiarrhythmic Drugs. Thirty healthy volunteers and 10 patients with congenital LQTS were studied. Healthy volunteers drank 2 L of grapefruit juice (in divided doses), or received 400 mg oral moxifloxacin, in a randomized crossover study. Patients with LQTS were tested with only grapefruit. Repeated baseline, off-drug, and on-drug (grapefruit or moxifloxacin) electrocardiograms were scanned and coded. QT measurements were done with electronic calipers.
RESULTS: In comparison to off-drug electrocardiograms, grapefruit juice led to significant rate-corrected QT (QTc) prolongation. The absolute net QTc prolongation from grapefruit was 14.0 ms (95% confidence interval 6.2-21.7 ms; P < .001). The QT-prolonging effects of grapefruit in healthy volunteers were comparable with those of moxifloxacin. The QT-prolonging effects of grapefruit juice were greater in female patients and particularly marked in patients with LQTS (net QTc prolongation 21.8 ms; 95% confidence interval 3.4-35.3 ms; P = .034).
CONCLUSION: Grapefruit juice, at doses tested, prolongs the QT interval. The effect is significant in healthy volunteers, greater in female patients, and more so in patients with LQTS.
Copyright © 2019 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adverse events; Drug-induced long QT syndrome; Proarrhythmia

Mesh:

Year:  2019        PMID: 31075442     DOI: 10.1016/j.hrthm.2019.04.039

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  3 in total

1.  COVID-19, Clinical Trials, and QT-Prolonging Prophylactic Therapy in Healthy Subjects: First, Do No Harm.

Authors:  Michael H Gollob
Journal:  J Am Coll Cardiol       Date:  2020-05-11       Impact factor: 24.094

Review 2.  Management of Congenital Long-QT Syndrome: Commentary From the Experts.

Authors:  Lee L Eckhardt; Elizabeth S Kaufman; Michael J Ackerman; Peter F Aziz; Elijah R Behr; Marina Cerrone; Mina K Chung; Michael J Cutler; Susan P Etheridge; Andrew D Krahn; Steven A Lubitz; Marco V Perez; Silvia G Priori; Jason D Roberts; Dan M Roden; Eric Schulze-Bahr; Peter J Schwartz; Wataru Shimizu; M Benjamin Shoemaker; Raymond W Sy; Jeffrey A Towbin; Sami Viskin; Arthur A M Wilde; Wojciech Zareba
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-07-09

3.  A Computational Pipeline to Predict Cardiotoxicity: From the Atom to the Rhythm.

Authors:  Pei-Chi Yang; Kevin R DeMarco; Parya Aghasafari; Mao-Tsuen Jeng; John R D Dawson; Slava Bekker; Sergei Y Noskov; Vladimir Yarov-Yarovoy; Igor Vorobyov; Colleen E Clancy
Journal:  Circ Res       Date:  2020-02-24       Impact factor: 17.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.